However, while "that's totally true," that still spells trouble for other 3-D printing stocks when HP starts "shipping in bulk," Cramer said on CNBC's "Cramer's Stop Trading" segment. In the meantime, Cramer sees shares of Stratasys going higher.

As for biotech stocks, Cramer noted Wells Fargo analyst Brian Abrahams' upgrade of BioMarin Pharmaceutical (BMRN) to outperform from market perform. Abrahams also boosted his price target to the range of $103 to $107 from $72 to $76.

"BioMarin is doing great things," Cramer said, as are Seattle Genetics (SGEN) and Isis Pharmaceuticals (ISIS) . These three companies could become the "heirs" to today's dominating biotech stocks, he said, referring to favorites Gilead Sciences (GILD) , Celgene (CELG) and Regeneron (REGN) .

The "junior" biotech stocks have the potential to become the "senior" biotech stocks, Cramer concluded, adding that he still likes Gilead, Celgene and Regeneron on the long the side.